{"id":"NCT02908672","sponsor":"Hoffmann-La Roche","briefTitle":"A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma","officialTitle":"A Phase III, Double-Blinded, Randomized, Placebo-Controlled Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFV600 Mutation-Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-01-13","primaryCompletion":"2019-10-11","completion":"2024-07-01","firstPosted":"2016-09-21","resultsPosted":"2020-11-19","lastUpdate":"2025-07-20"},"enrollment":514,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Melanoma"],"interventions":[{"type":"DRUG","name":"Atezolizumab","otherNames":[]},{"type":"DRUG","name":"Atezolizumab Placebo","otherNames":[]},{"type":"DRUG","name":"Cobimetinib","otherNames":[]},{"type":"DRUG","name":"Vemurafenib","otherNames":[]},{"type":"DRUG","name":"Vemurafenib Placebo","otherNames":[]}],"arms":[{"label":"Atezolizumab + Cobimetinib + Vemurafenib + Vemurafenib Placebo","type":"EXPERIMENTAL"},{"label":"Atezolizumab Placebo + Cobimetinib + Vemurafenib","type":"EXPERIMENTAL"}],"summary":"This is a Phase III, double-blinded, placebo-controlled, randomized, multicenter study designed to evaluate the efficacy, safety, and pharmacokinetics of atezolizumab + cobimetinib + vemurafenib compared with placebo + cobimetinib + vemurafenib in patients with previously untreated BRAFv600 mutation-positive metastatic or unresectable locally advanced melanoma.","primaryOutcome":{"measure":"Progression-Free Survival (PFS), as Determined by Investigator Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1","timeFrame":"Baseline up to PD or death due to any cause, whichever occurred first (up to approximately 33 months)","effectByArm":[{"arm":"Arm A: Pbo + Cobi + Vem","deltaMin":10.6,"sd":null},{"arm":"Arm B: Atezo + Cobi + Vem","deltaMin":15.1,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0224"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":null},"locations":{"siteCount":110,"countries":["United States","Australia","Austria","Belgium","Brazil","Canada","France","Germany","Greece","Hungary","Israel","Italy","Netherlands","New Zealand","Poland","Portugal","Russia","South Korea","Spain","United Kingdom"]},"refs":{"pmids":["36653848","36460017","35131452","33476492","32534646"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":21,"n":232},"commonTop":["Diarrhoea","Blood creatine phosphokinase increased","Rash","Pyrexia","Arthralgia"]}}